New drug duo aims to tackle Tough-to-Treat myeloma

NCT ID NCT06669247

First seen Apr 23, 2026 · Last updated May 15, 2026 · Updated 4 times

Summary

This study tests a new experimental drug, REGN7945, combined with another experimental drug, linvoseltamab, in people whose multiple myeloma has returned or not responded to at least three prior treatments. The goal is to see if the combination is safer and works better than linvoseltamab alone. About 186 participants will be enrolled in this first-in-human trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Alfred Hospital

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • Illawarra Cancer Care Centre

    RECRUITING

    Wollongong, New South Wales, 2500, Australia

  • Pindara Private Hospital

    RECRUITING

    Benowa, Queensland, 4217, Australia

  • Royal Adelaide Hospital

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • St Vincents Hospital Melbourne

    RECRUITING

    Melbourne, Victoria, 3065, Australia

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, M20 4BQ, United Kingdom

  • University College London Hospitals

    RECRUITING

    London, NW1 2PG, United Kingdom

Conditions

Explore the condition pages connected to this study.